<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189670</url>
  </required_header>
  <id_info>
    <org_study_id>AERO-B03</org_study_id>
    <nct_id>NCT00189670</nct_id>
  </id_info>
  <brief_title>Randomized Phase II Trial of Dose Dense Docetaxel in N+ Breast Cancer</brief_title>
  <official_title>A Phase II Randomized Trial of 6 TEC Every 3 Weeks, Versus 4 EC Followed by 4 Taxotere Every 2 Weeks, Versus 4 Taxotere Followed by 4 EC Every 2 Weeks in Node Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Européenne de Recherche en Oncologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aventis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Association Européenne de Recherche en Oncologie</source>
  <brief_summary>
    <textblock>
      To screen a dose-dense arm to be used in a future large scale phase III trial. Primary
      endpoint is safety; secondary endpoints are disease free survival and overall survival. A
      total of 100 patients were included.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Node Positive Breast Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>6 TEC q 3 weeks</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>4 EC q 2 weeks followed by 4 TXT q 2 weeks</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>4 TXT q 2 weeks followed by 4 EC q 2 weeks</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with histologically proven breast cancer

          -  Surgical resection performed with clear margins (R0 resection)

          -  At least 1 histologically proven involved axillary node

          -  ER + or ER-

          -  Interval between surgery (2nd surgical procedure in case of multiple procedures) and
             randomization inferior to 60 days

          -  Aged over 18 years, and more than 10-year life expectancy

          -  ECOG performance status 0-1

          -  Signed informed consent form prior to randomization

        Exclusion Criteria:

          -  Bilateral breast cancer

          -  Inflammatory breast cancer

          -  Personal history of breast cancer

          -  Immunohistochemical only node involvement

          -  Intraductal breast cancer

          -  Distant metastases

          -  Contraindication to any drug contained in the chemotherapy regimens

          -  Any serious active disease or co-morbid medical condition including recent history of
             severe sepsis and digestive inflammatory disease

          -  Poor renal function (creatinin level &gt; 120 micromol/L), poor hepatic function (total
             bilirubin level &gt; 1 UNL), transaminases &gt; 2.5 UNL)

          -  Poor bone marrow reserve as defined by neutrophils &lt; 1.5 G/L or platelets &lt; 100 G/L;
             Hemoglobin &lt; 10 G/dL

          -  Poor contractile cardiac function (LVEF &lt; 50%)

          -  Coronary disease

          -  Any history of cancer during the last 5 years, with the exception of basal cell
             carcinomas or stage 0 (in situ) cervical carcinoma

          -  Pregnancy or breast feeding

          -  Absence of contraception in non menopausal women

          -  Adult patient unable to give informed consent because of intellectual impairment

          -  Concomitant participation to another trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Pascal Piedbois, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Association Europeenne de Recherche en Oncologie</affiliation>
  </overall_official>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>September 12, 2005</last_update_submitted>
  <last_update_submitted_qc>September 12, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

